Overview
Tomofumi Miyamoto practices practicing medicine in Higashi, Japan.
Their clinical expertise encompasses Acute Promyelocytic Leukemia, Gastritis, and Kawasaki Disease.
They are actively involved in clinical research, co-authoring 76 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Tomofumi Miyamoto
Is Tomofumi Miyamoto a top-rated expert for Acute Promyelocytic Leukemia?
MediFind is an objective health platform that identifies experts based on real-world data. Tomofumi Miyamoto is classified as an Experienced expert for Acute Promyelocytic Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Tomofumi Miyamoto participate in research or clinical trials?
Yes. Tomofumi Miyamoto has published 76 articles and abstracts on conditions like Acute Promyelocytic Leukemia. You can view a list of Tomofumi Miyamoto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Promyelocytic LeukemiaMiyamoto isExperienced. Learn about Acute Promyelocytic Leukemia.
- GastritisMiyamoto isExperienced. Learn about Gastritis.
- Kawasaki DiseaseMiyamoto isExperienced. Learn about Kawasaki Disease.